Abstract
Circadian rhythm disruptions have emerged as a critical factor in the development and progression of Alzheimers disease (AD). These disruptions affect key processes such as beta-amyloid (A) aggregation, tau protein hyperphosphorylation, and impaired protein clearance, all of which contribute to neurodegeneration. Melatonin, a hormone that regulates the circadian cycle, plays a neuroprotective role but decreases with age, especially in AD patients. Research suggests that melatonin supplementation may help mitigate the effects of A accumulation, tau-related pathology, and oxidative stress. Additionally, bright light therapy (BLT) has been shown to improve circadian rhythm regulation, enhancing sleep quality and cognitive function in individuals with AD. This review highlights the intricate relationship between circadian rhythm disruptions and AD pathology and examines therapeutic interventions such as melatonin and BLT that offer potential benefits in managing the disease.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call